Citigroup Inc. Buys 59,669 Shares of ADMA Biologics Inc $ADMA

Citigroup Inc. increased its stake in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 6.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,001,852 shares of the biotechnology company's stock after buying an additional 59,669 shares during the quarter. Citigroup Inc. owned approximately 0.42% of ADMA Biologics worth $19,877,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ bought a new position in ADMA Biologics during the 1st quarter worth $35,000. Tsfg LLC acquired a new stake in shares of ADMA Biologics during the 1st quarter worth $51,000. Harvest Fund Management Co. Ltd acquired a new stake in ADMA Biologics in the first quarter valued at about $52,000. Farther Finance Advisors LLC boosted its stake in ADMA Biologics by 1,149.1% in the first quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after buying an additional 2,505 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in ADMA Biologics in the fourth quarter valued at about $85,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Buying and Selling at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the completion of the transaction, the director owned 478,194 shares in the company, valued at approximately $10,190,314.14. This represents a 2.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. The trade was a 17.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold 464,621 shares of company stock worth $9,644,269 in the last quarter. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Stock Up 3.8%

Shares of NASDAQ ADMA traded up $0.64 during midday trading on Monday, hitting $17.63. 952,779 shares of the stock traded hands, compared to its average volume of 3,140,264. The company has a market cap of $4.21 billion, a PE ratio of 20.51 and a beta of 0.38. ADMA Biologics Inc has a one year low of $13.50 and a one year high of $25.67. The business has a 50 day moving average price of $18.29 and a two-hundred day moving average price of $18.87. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%. ADMA Biologics's revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.13 earnings per share. On average, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Raymond James Financial lifted their target price on ADMA Biologics from $25.00 to $32.00 and gave the stock a "strong-buy" rating in a report on Thursday, May 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.